Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.32 |
| ▸ | MMP9 | P14780 | 2/20 | 0.32 |
| ▸ | MMP8 | P22894 | 2/20 | 0.32 |
| ▸ | MMP13 | P45452 | 2/20 | 0.32 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18489379 | 1.00 | ALDH1A1 (0.33) | ALDH1A1MMP2MMP9MMP8MMP13 | |
| SCHEMBL3228504 | 0.82 | APLNR (0.39) | ALDH1A1 | |
| SCHEMBL24322112 | 0.80 | SMN1; SMN2 (0.45) | ALDH1A1 | |
| SCHEMBL29515045 | 0.80 | SMN1; SMN2 (0.45) | ALDH1A1 | |
| SCHEMBL24021330 | 0.80 | MMP2 (0.30) | MMP2MMP9MMP8MMP13 | |
| SCHEMBL29480717 | 0.79 | FDFT1 (0.34) | MMP2MMP9MMP8MMP13FDFT1 | |
| SCHEMBL22735953 | 0.79 | FDFT1 (0.34) | MMP2MMP9MMP8MMP13FDFT1 | |
| SCHEMBL5738845 | 0.78 | PTGS1 (0.35) | ALDH1A1 | |
| SCHEMBL18504414 | 0.77 | ALDH1A1 (0.39) | ALDH1A1MMP2MMP9MMP13 | |
| SCHEMBL29108191 | 0.77 | CYP11B1 (0.33) | FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3341370-B1 | CGRP RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2021-04-28 | — | — | EP | disclosed |
| EP-3334721-B1 | CGRP RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2021-04-28 | — | — | EP | disclosed |
| US-9708297-B2 | CGRP receptor antagonists | ELI LILLY AND COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| US-9637495-B2 | CGRP receptor antagonists | ELI LILLY AND COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637495-B2 | CGRP receptor antagonists | ELI LILLY AND COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637495-B2 | CGRP receptor antagonists | ELI LILLY AND COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| US-20170044138-A1 | CGRP RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2017-02-16 | — | — | US | disclosed |
| US-20170044163-A1 | CGRP RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2017-02-16 | — | — | US | disclosed |
| US-20170044163-A1 | CGRP RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2017-02-16 | — | — | US | disclosed |
| US-20170044163-A1 | CGRP RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044163-A1 | CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CCKBR | ALDH1A1 1467/4885MMP2 2182/4885MMP9 2268/4885 |
| US-20170044138-A1 | CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CCKBR | ALDH1A1 1467/4885MMP2 2182/4885MMP9 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.